Chemistry:Fexagratinib
From HandWiki
Fexagratinib (AZD4547) is an experimental drug which acts as an inhibitor of the fibroblast growth factor receptors, having high affinity for FGFR1, FGFR2 and FGFR3 and weaker activity at FGFR4. It has reached clinical trials in humans against several forms of cancer, but has had only limited use as a medicine due to an unfavorable side effect profile, though it may have some applications in combination with other drugs. However it is still widely used in cancer research.[1][2][3][4][5]
References
- ↑ "AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family". Cancer Research 72 (8): 2045–2056. April 2012. doi:10.1158/0008-5472.CAN-11-3034. PMID 22369928.
- ↑ "FGF receptors: cancer biology and therapeutics". Medicinal Research Reviews 34 (2): 280–300. March 2014. doi:10.1002/med.21288. PMID 23696246.
- ↑ "FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)". International Journal of Molecular Medicine 38 (1): 3–15. July 2016. doi:10.3892/ijmm.2016.2620. PMID 27245147.
- ↑ "Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma". Urologic Oncology 40 (2): 25–36. February 2022. doi:10.1016/j.urolonc.2021.10.003. PMID 34840077.
- ↑ "The Application of Artificial Intelligence and Drug Repositioning for the Identification of Fibroblast Growth Factor Receptor Inhibitors: A Review". Advanced Biomedical Research 13: 9. 2024. doi:10.4103/abr.abr_170_23. PMID 38525398.
 |  |
